PFIZER Aktie

 

Pfizer (NYSE:PFE) and Merck (NYSE:MRK) both just closed earnings chapters that frame the 2026 dividend debate clearly. Pfizer wrapped fiscal 2025 with a $0.66 adjusted EPS Q4 beat. Merck followed with a Q1 2026 report dominated by a $9 billion Cidara acquisition charge. Two very different income stories for yield hunters. One Pays You to ... Pfizer vs Merck: Chasing High Yield vs Higher Returns...

Whichever one you choose, you'll need patience before you can see solid returns....

It is finally bouncing back after several challenging years....

PFE targets a catalyst-rich 2026 with pivotal obesity and oncology studies, key data readouts, and regulatory decisions across its pipeline....

Pfizer (NYSE:PFE) is one of those names where the headline narrative (COVID hangover, patent cliff) keeps overshadowing what is actually a defensive cash machine trading at a single-digit forward multiple. After running the numbers, my view leans constructive, and the 24/7 Wall St. price target reflects that. PFE stock trades at $26.18, and our 24/7 ... Why Pfizer's Current Price May Be Too Cheap to Ignore...

AbbVie and Pfizer chart distinct paths in revenue growth, risk, and valuation. Explore how their financials and strategies stack up for investors this year....

Pfizer could attract investors if Warsh's "regime change" at the Fed leads to market turbulence....

NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat Pfizer mit einem Kursziel von 35 US-Dollar auf "Buy" belassen. Die beiden Pharmakonzerne Pfizer und Biontech hätten auf der ASCO-Krebstagung Updates zu ihren Programmen zur Erstlinientherapie ......

NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Pfizer mit einem Kursziel von 30 US-Dollar belassen. Der Fokus im Onkologieportfolio sei zunächst auf Sigvotatug Vedotin gegen Lungenkrebs (NSCLC) gerichtet, schrieb Chris Schott ......

Pfizer is an over-100-year-old drug company going through a rough patch, which has happened before....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) announced detailed progression-free and overall survival results from Cohort 3 of the Phase 3 BREAKWATER trial. This randomized cohort evaluated BRAFTOV......

NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) announced detailed results from the pivotal Phase 3 TALAPRO-3 study evaluating TALZENNA (talazoparib), an oral PARP inhibitor, in combination with XTAND......

NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) on Friday reported seven-year follow-up results from the Phase 3 CROWN trial showing that LORBRENA significantly improved progression-free survival comp......

Patients had a 55% likelihood of remaining alive without disease progression at seven years, and median progression-free survival was not reached with LORBRENA Updated follow-up analysis solidifies LORBRENA as a preferred standard of care, building upon five-year results NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced unprecedented seven-year follow-up results from the Phase 3 CROWN trial evaluating LORBRENA® (lorlatinib, a third-generation ALK inhibitor, available in Europe under the brand name LORVIQUA®) versus XALKORI® (crizotinib) in people with previously untreated, anaplastic lymphoma kinase (ALK)-positive advanced or metastatic non-small cell lung cancer (NSCLC). At seven years, patients treated with LORBRENA had a 55% likelihood of remaining alive without disease progression (95% Confidence Interval [CI], 46-63) compared to 3% (95% CI, 1-8) in the XALKORI treatment arm. Further, an updated analysis at seven years of median follow-up showed that investigator-assessed median pr...

The agreement covers antibody-drug conjugates with new payloads and multi-specific antibodies featuring distinct immune-engaging mechanisms. The portfolio consists of eight drug candidates originating from Innovent Biologics and four The post Pfizer and Innovent Biologics sign $10.5bn cancer drug development deal appeared first on Pharmaceutical Business review....

Pfizer schließt eine der größten Biotech-Kooperationen des Jahres ab und setzt dabei auf chinesische Krebsforschung. Was steckt hinter dem 10,5-Milliarden-Deal mit Innovent Biologics? --- Der Deal fällt in eine Phase, in der sich westliche Pharmakonzerne geradezu auf chinesische Biotech-Pipelines stürzen. Das Volumen solcher Lizenzabkommen aus Greater China hat sich laut dem Datenanbieter Pharmcube zwischen 2021 und dem vergangenen Jahr fast verzehnfacht und erreichte 2024 einen Rekordwert von rund 138 Milliarden US-Dollar..

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

China's Innovent Biologics has signed a global collaboration with pharmaceutical giant Pfizer worth up to US$10.5 billion to jointly develop 12 cancer treatment programmes. The Hong Kong-listed drug maker said it would receive an upfront payment of US$650 million from Pfizer, and it is eligible for up to US$9.85 billion tied to development, regulatory and commercial milestone payments, according to an exchange filing on Friday. Innovent, which is based in Suzhou in China's eastern Jiangsu......

Der US-amerikanische Pharma-Riese Pfizer verstärkt seine Entwicklungspipeline. Für bis zu 10,5 Milliarden Dollar sichert sich das Unternehmen die Rechte an zwölf Wirkstoffen der chinesischen Innovent Biologics. Die Aktie der Asiaten gewinnt an der Heimatbörse nach Bekanntwerden des Deals um rund zehn Prozent....